ORIGINAL PAPER
Omentin rs2274907 gene polymorphism and the risk of metabolic syndrome: a preliminary report
Submission date: 2018-12-06
Acceptance date: 2018-12-14
Publication date: 2018-12-31
Medical Studies 2018;34(4):267-275
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Omentin is a relatively recently examined adipokine that appears to be associated with metabolic risk factors and metabolic syndrome.
Aim of the research:
To analyse the relationship between omentin rs2274907 gene polymorphism and the risk of metabolic syndrome and its components.
Material and methods:
Genetic material and the clinical data of 219 individuals were analysed, including 108 with metabolic syndrome (MetS), diagnosed on the basis of International Diabetes Federation (IDF) criteria. Omentin rs2274907 mutation was detected using the PCR-RFLP method.
Results:
The genotype distribution showed no deviation from the Hardy-Weinberg equilibrium (2 = 3.055; p = 0.080). No significant association was found between the Asp allele of omentin rs2274907 and MetS or its components, when compared to the Val allele (p = 0.198). The Val/Asp, Asp/Asp and Val/Asp + Asp/Asp genotypes also showed no association with MetS and its components when compared to Val/Val genotype (p = 0.662; p = 0.627; p = 0.938, respectively). Only a statistically insignificant tendency towards a more frequent occurrence of the Val/Asp genotype in subjects with MetS (42.60% vs. 34.24%) and more frequent occurrence of the Asp/Asp genotype in the control group (53.15% vs. 44.44%) was reported. Statistically significant correlations between omentin Val109Asp polymorphism and MetS risk and its components were not found in the model adjusted for age, sex, smoking habits or physical activity.
Conclusions:
The results of the conducted research did not show any significant relationship between omentin polymorphism Val109Asp and MetS risk. There were no associations of this polymorphism with any of the MetS components. It is necessary to conduct further research on a larger population.
Omentin is a relatively recently examined adipokine that appears to be associated with metabolic risk factors and metabolic syndrome.
Aim of the research:
To analyse the relationship between omentin rs2274907 gene polymorphism and the risk of metabolic syndrome and its components.
Material and methods:
Genetic material and the clinical data of 219 individuals were analysed, including 108 with metabolic syndrome (MetS), diagnosed on the basis of International Diabetes Federation (IDF) criteria. Omentin rs2274907 mutation was detected using the PCR-RFLP method.
Results:
The genotype distribution showed no deviation from the Hardy-Weinberg equilibrium (2 = 3.055; p = 0.080). No significant association was found between the Asp allele of omentin rs2274907 and MetS or its components, when compared to the Val allele (p = 0.198). The Val/Asp, Asp/Asp and Val/Asp + Asp/Asp genotypes also showed no association with MetS and its components when compared to Val/Val genotype (p = 0.662; p = 0.627; p = 0.938, respectively). Only a statistically insignificant tendency towards a more frequent occurrence of the Val/Asp genotype in subjects with MetS (42.60% vs. 34.24%) and more frequent occurrence of the Asp/Asp genotype in the control group (53.15% vs. 44.44%) was reported. Statistically significant correlations between omentin Val109Asp polymorphism and MetS risk and its components were not found in the model adjusted for age, sex, smoking habits or physical activity.
Conclusions:
The results of the conducted research did not show any significant relationship between omentin polymorphism Val109Asp and MetS risk. There were no associations of this polymorphism with any of the MetS components. It is necessary to conduct further research on a larger population.
REFERENCES (37)
1.
Gasparotto AS, Borges DO, Zandoná MR, Ramos MJ, Meihnardt NG, Mattevi VS. Adiponectin promoter polymorphisms are predictors of lipid profile improvement after bariatric surgery. Genet Mol Biol 2017; 40: 736-42.
2.
Gao L, Wu L, Zhang M, Zhao X, Cheng H, Mi J. Genderspecific association of the rs6499640 polymorphism in the FTO gene with plasma lipid levels in Chinese children. Genet Mol Biol 2018; 41: 397-402.
3.
Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005; 1732: 96-102.
4.
Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-61.
5.
de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-61.
6.
Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-8.
7.
Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G, Fernández-Real JM. Circulating omentin concentration increases after weight loss. Nutr Metab 2010; 7: 27.
8.
Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, del Castillo D, Richart C. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60.
9.
Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88: 29-33.
10.
Wittenbecher C, Menzel J, Carstensen-Kirberg M, Biemann R, di Giuseppe R, Fritsche A, Isermann B, Herder C, Aleksandrova K, Boeing H, Weikert C, Schulze MB. Omentin-1, adiponectin, and the risk of developing type 2 diabetes. Diabetes Care 2016; 39: e79-80.
11.
Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 514-7.
12.
Buyukinan M, Atar M, Can U, Pirgon O, Guzelant A, Deniz I. The association between serum vaspin and omentin-1 levels in obese children with metabolic syndrome. Metab Syndr Relat Disord 2018; 16: met.2017.0133.
13.
Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA, Aquilante CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetol Metab Syndr 2014; 6: 4.
14.
Kilic DC, Oguz A, Uzunlulu M, Celik S, Koroglu G. Plasma omentin-1 levels are similar in nondiabetic metabolic syndrome patients and healthy subjects. J Endocrinol Metabol 2011; 1: 182-7.
15.
Tan B, Adya R, Farhatullah S, Lewandowski K, O’Hare P, Lehnert H, Randeva HS. Omentin-1, a novel adipokine, is decreased in overweight insulin resistant women with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-8.
16.
Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, Kataoka T, Nagao T, Okumura S, Shinoda N, Kato B, Sakai S, Kato M, Marui N, Ishii H, Amano T, Matsubara T, Murohara T. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis 2016; 251: 299-304.
17.
Schäffler A, Zeitoun M, Wobser H, Buechler C, Aslanidis C, Herfarth H. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovasc Diabetol 2007; 6: 3.
18.
Isakova ZT, Talaibekova ET, Asambaeva DA, Kerimkulova AS, Lunegova OS, Aldasheva NM, Aldashev AA. A polymorphic marker Val109Asp in the omentin gene are associated with abdominal obesity in the Kyrgyz population. Probl Endocrinol 2016; 62: 4-8.
19.
Zatoński WA, Mańczuk M; Polish-Norwegian Study (PONS). Research on chronic non-communicable diseases in European high risk countries – study design. Ann Agric Environm Med 2011; 18: 203-6.
20.
Suliga E, Kozieł D, Cieśla E, Rębak D, Głuszek S. Dietary patterns in relation to metabolic syndrome among adults in Poland: a cross-sectional study. Nutrients 2017; 9: pii: E1366.
21.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
22.
International Physical Activity Questionnaire (IPAQ) — The Long Form. Available online: http://www.sdp.univ.fvg.it/sit... default/files/IPAQ_English_self-admin_long.pdf (accessed on 15 March 2010).
23.
Rębak D, Suliga E, Głuszek S. Metabolic syndrome and professional aptitude. Studia Medyczne 2015; 31: 286-94.
24.
Urbanová M, Dostálová I, Trachta P, Drápalová J, Kaválková P. Serum concentrations and subcutaneous adipose tissue mRNA expression of omentin in morbid obesity and type 2 diabetes mellitus: the effect of very-low-calorie diet, physical activity and laparoscopic sleeve gastrectomy. Physiol Res 2014; 8408: 207-18.
25.
Herder C, Kannenberg JM, Niersmann C, Huth C, Carstensen-Kirberg M, Wittenbecher C, Schulze M, Blüher M, Rathmann W, Peters A, Roden M, Meisinger C, Thorand B. Independent and opposite associations of serum levels of omentin-1 and adiponectin with increases of glycaemia and incident type 2 diabetes in an older population: KORA F4/FF4 study. Eur J Endocrinol 2017; 177: 277-86.
26.
Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metab Clin Exp 2014; 63: 1265-71.
27.
Cătoi AF, Suciu Ş, Pârvu AE, Copăescu C, Galea RF, Buzoianu AD, Vereşiu IA, Cătoi C, Pop ID. Increased chemerin and decreased omentin-1 levels in morbidly obese patients are correlated with inculin resistance, oxidative stress and chronic inflammation. Clujul Med 2014; 87: 19-26.
28.
Guvenc Y, Var A, Goker A, Kuscu NK. Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J Int Med Res 2016; 44: 796-805.
29.
Elsaid NH, Sadik NA, Ahmed NR, Fayez SE, Mohammed NA. Serum omentin-1 levels in type 2 diabetic obese women in relation to glycemic control, insulin resistance and metabolic parameters. J Clin Transl Endocrinol 2018; 13: 14-9.
30.
Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4: 37.
31.
Stejskal D, Vaclavik J, Smekal A, Svobodova G, Richterova R, Svestak M. Omentin-1 levels in patients with premature coronary artery disease, metabolic syndrome and healthy controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160: 219-21.
32.
Suliga E, Wawszczak M, Gluszek S. The roles of vaspin, chemerin, and omentin in the determination of metabolic syndrome. Medical Studies 2018; 34: 160-77.
33.
Splichal Z, Bienertova-Vasku J, Novak J, Zlamal F, Tomandl J, Tomandlova M, Forejt M, Havlenova S, Jackowska A, Vasku A. The common polymorphism Val109Asp in the omentin gene is associated with daily energy intake in the Central-European population. Nutr Neurosci 2015; 18: 41-8.
34.
Kohan L, Safarpur M, Abdollahi H. Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease. Mol Biol Res Commun 2016; 5: 11-7.
35.
Askari SN, Zehra S, Azhar A. Association of single nucleotide missence polymorphism Val109Aspof omentin-1 gene and coronary artery disease in Pakistani population: multicenter study. Pak J Med Sci 2017; 33: 1128-33.
36.
Yörük U, Yaykaşli KO, Özhan H, Memişoğullari R, Karabacak A, Bulur S, Aslantaş Y, Başar C, Kaya E. Association of omentin Val109Asp polymorphism with coronary artery disease. Anatolu J Cardiol 2014; 14: 511-4.
37.
Jamshidi J, Ghanbari M, Asnaashari A, Jafari N, Valizadeh GA. Omentin Val109Asp polymorphism and risk of coronary artery disease. Asian Cardiovasc Thorac Ann 2017; 25: 199-203.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
